Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III open-label single-arm study of intravenous human immunoglobulin for primary immune thrombocytopenia
CTR20241512Phase 3Completed
- Sponsor
- Weiguang Biological
- Start
- Apr 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of immune globulin in immune thrombocytopenia (ITP), sponsored by Weiguang Biological. Started Apr 2024; status: completed.
02
Drugs
immune globulin
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on CTR20241512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241512.